WFDC2 and ovarian cancer: Moore et al. [23] conducted a follow-up study with 89 ovarian cancer patients and showed that patients with serum HE4 levels < 500 pM had a 5-year survival rate of 59%, but patients with HE4 levels > 500 pM had a poor 5-year survival rate of 27%.